Interim Postmarket Data Release May Compromise Trials – FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Members of FDA's Neurological Devices Panel questioned the wisdom of asking sponsors to present interim results of ongoing post-approval trials during a meeting Jan. 26